Arrowhead Research | ARWR - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Novartis USD 4.64B 445M 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09
Xencor USD -4.27M 1.76M 2025-12